Definitive Contract 75N93019C00036
Award Date 9/1/19
Potential Completion Date 8/31/21
Potential Value $311K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Lawrence, KS 66047, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $224,992 firm fixed price definitive contract to Hafion Inc., a self-certified small disadvantaged and woman-owned small business, to conduct research and development on generating synergy between protein and non-protein macromolecular adjuvants. The contract, which was not set aside, was completed in July 2018. Hafion has also received other prime and...
- This firm fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS), to Access To Advanced Health Institute (AAHI), doing business as Aahi, Idri, and Infectious Disease Research Institute. The $2,980 contract is for infectious disease research and development, specifically related to vaccine adjuvants. AAHI is a non-profit biotech research institute that combines academic...
- This $299,040 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to design and synthesize a new PLGA-based nanoparticle with an optimal protein-adjuvant formulation that combines targeting and controlled delivery for immunization...
- This federal contract award to Neovaxsyn Inc., a minority-owned small disadvantaged business, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services. The $300,000 firm fixed-price contract supports the development of a next-generation immunoprevention platform against HIV-1, with a final completion date of October 31, 2025. The contract was awarded under the Small Business Innovation Research (SBIR) program, which...
- <p>This federal contract award with ID HHSN272201200386P was made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to the small business contractor IG Assets Inc. The $99,750.00 firm fixed-price purchase order contract was awarded on April 10, 2012 with a completion date of April 28, 2013. The contract is designated as a total small business set-aside.</p>
- This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
- This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to International AIDS Vaccine Initiative Inc. (IAVI), a non-profit organization. The $713,906.00 award supports the development of nanoparticle-based delivery systems for human immunodeficiency virus type 1 (HIV-1) biomolecules. The contract has a performance period ending on December 15, 2021 and utilizes a Cost...
- This is a $18,576,013.05 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute located in Seattle, Washington. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant infections, and emerging infectious diseases, under NIAID's Broad Agency Announcement (BAA) Research Area 001. AAHI...
- This firm-fixed-price SBIR Phase I contract was awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a for-profit biopharmaceutical company. The $599,629 contract funds the "Rational Development of a Combination Nanoparticle Adjuvant for Influenza", which involves research and development of novel adjuvants and other medical countermeasures. HDT Bio Corp has previously served as a prime contractor on other HHS...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed price purchase order contract to Advanced Bioadjuvants, LLC, a self-certified small disadvantaged business. The contract is for license fees related to the Adjuplex trademark, patents, and trade secret manufacturing process, which NIAID will use to combine with human vaccines for clinical trials. The contract has a 12-month...